文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌的立体定向体部放疗:现状如何?

Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
PubMed 文献 · Pract Radiat Oncol · 2017-12-02

本文通过系统文献综述评估SBRT在高危前列腺癌中的生化无病生存(bDFS)与毒性证据。共纳入20项研究,单药SBRT的5年bDFS为81%–91%,boost为90%–98%;晚期3级泌尿生殖毒性单药为0%–4.4%,boost为0%–2.3%。证据基于观察性研究,属III级证据,SBRT单药应谨慎用于高度选择的高危患者。

要点

  • 高危前列腺癌SBRT单药5年bDFS为81%–91%,boost为90%–98%。
  • 晚期3级泌尿生殖毒性单药为0%–4.4%,boost为0%–2.3%。
  • 证据为观察性研究、样本少、随访短,属III级证据。

核心结论

  • 高危前列腺癌SBRT证据基于观察性研究,样本量相对少且随访短,属III级证据。
  • SBRT boost理想情况下应在临床试验中验证。
  • SBRT单药在临床试验外应谨慎用于高度选择的高危患者。

研究设计与样本

  • 系统文献综述,检索PubMed和Embase数据库,共检出8862篇文章。
  • 纳入20项研究,中位随访1.6至7年,高危患者接受SBRT单药或boost且报告bDFS。
  • 另选19项报告高危患者HDR近距离治疗单药或boost的研究用于比较,并比较近期发表的涉及高危患者的3期试验数据。

主要发现

  • SBRT单药研究5年bDFS为81%至91%,SBRT boost研究为90%至98%。
  • HDR单药研究5年bDFS为85%至93%,HDR boost研究为72%至93%。
  • SBRT单药晚期3级泌尿生殖毒性发生率为0%至4.4%,SBRT boost为0%至2.3%。

临床怎么用

  • 高危前列腺癌SBRT boost宜在临床试验中验证后应用。
  • SBRT单药在临床试验外应仅谨慎用于高度选择的高危患者。

局限性

  • 证据基于观察性研究,患者数相对少且随访时间短,属III级证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of localized prostate cancer. This trend combined with declining use of brachytherapy (BT) has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to review the current evidence of biochemical disease-free survival (bDFS) and toxicity of SBRT in high-risk (HR) prostate cancer. METHODS AND MATERIALS: A search was carried out on the PubMed and Embase databases. Studies were included if HR patients were treated using SBRT monotherapy or as a boost and bDFS was reported. Selected high-dose-rate (HDR) BT studies including HR patients from published reviews were selected to compare with SBRT results. Data from recent published phase 3 trials involving HR patients were also compared. RESULTS: Our search yielded 8862 articles. Of these, 20 studies with a median follow-up from 1.6 to 7 years were included in this review. The 5-year bDFS was 81% to 91% in monotherapy studies and 90% to 98% in boost studies. For reference, 19 studies that reported treating HR patients with HDR monotherapy or boost were selected. The 5-year bDFS in HDR monotherapy studies and boost studies was 85% to 93% and 72% to 93%, respectively. The incidence of late grade 3 genitourinary toxicity was 0% to 4.4% and 0% to 2.3% in SBRT monotherapy and SBRT boost studies, respectively. CONCLUSION: The evidence for SBRT in HR patients in this review is based on observational studies with relatively few patients and short follow-up (level III evidence). Based on these data and the principles surrounding treatment, SBRT boost should ideally be validated in clinical trials. SBRT monotherapy should be used cautiously in highly selected HR patients outside of a clinical trial. SUMMARY: Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of clinically localized prostate cancer. This trend, combined with the decline in the use of brachytherapy, has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to establish the current evidence of biochemical and toxicity outcomes of SBRT in high-risk prostate cancer.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Motta A, Roach M. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now? Pract Radiat Oncol. 2017. PMID: 29339046. doi:10.1016/j.prro.2017.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。